These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 9337181)

  • 1. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial.
    Syvänne M; Taskinen MR; Nieminen ; Manninen V; Kesäniemi YA; Pasternack A; Nawrocki JW; Haber H; Frick MH
    Control Clin Trials; 1997 Feb; 18(1):93-119. PubMed ID: 9055055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
    Sacks FM; Pasternak RC; Gibson CM; Rosner B; Stone PH
    Lancet; 1994 Oct; 344(8931):1182-6. PubMed ID: 7934538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.
    Syvänne M; Whittall RA; Turpeinen U; Nieminen MS; Frick MH; Kesäniemi YA; Pasternack A; Humphries SE; Taskinen MR
    Atherosclerosis; 2004 Feb; 172(2):267-72. PubMed ID: 15019536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
    Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
    J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
    Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.
    Karpe F; Taskinen MR; Nieminen MS; Frick MH; Kesäniemi YA; Pasternack A; Hamsten A; Syvänne M
    Atherosclerosis; 2001 Jul; 157(1):181-7. PubMed ID: 11427219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.
    Nikkilä EA; Viikinkoski P; Valle M; Frick MH
    Br Med J (Clin Res Ed); 1984 Jul; 289(6439):220-3. PubMed ID: 6430414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.